The project aims to develop a combined molecular signature of metabolomics and miRNAs from urine of patients diagnosed with prostate cancer for stratification for active surveillance or immediate intervention. A consortium between the companies Atrys Health (Spain) and DINÁMICA (Colombia) has been established to carry out the project. Both companies will use cohorts of patients diagnosed early with non-aggressive prostate cancer and who meet the criteria for inclusion in active surveillance programmes.

In both cohorts, combined molecular signatures of metabolomic profiles and miRNAs will be sought from samples obtained through non-invasive liquid biopsy procedures from patient urine.